GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galmed Pharmaceuticals Ltd (NAS:GLMD) » Definitions » PB Ratio

GLMD (Galmed Pharmaceuticals) PB Ratio : 0.24 (As of Dec. 13, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Galmed Pharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-13), Galmed Pharmaceuticals's share price is $2.97. Galmed Pharmaceuticals's Book Value per Share for the quarter that ended in Sep. 2024 was $12.23. Hence, Galmed Pharmaceuticals's PB Ratio of today is 0.24.

The historical rank and industry rank for Galmed Pharmaceuticals's PB Ratio or its related term are showing as below:

GLMD' s PB Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.98   Max: 18.18
Current: 0.24

During the past 12 years, Galmed Pharmaceuticals's highest PB Ratio was 18.18. The lowest was 0.01. And the median was 0.98.

GLMD's PB Ratio is ranked better than
97.81% of 1279 companies
in the Biotechnology industry
Industry Median: 2.48 vs GLMD: 0.24

During the past 12 months, Galmed Pharmaceuticals's average Book Value Per Share Growth Rate was -73.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -55.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -46.10% per year.

During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Galmed Pharmaceuticals was 53.60% per year. The lowest was -55.40% per year. And the median was -27.10% per year.

Back to Basics: PB Ratio


Galmed Pharmaceuticals PB Ratio Historical Data

The historical data trend for Galmed Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galmed Pharmaceuticals PB Ratio Chart

Galmed Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.75 1.50 1.50 0.94 0.17

Galmed Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.17 0.16 0.15 0.56

Competitive Comparison of Galmed Pharmaceuticals's PB Ratio

For the Biotechnology subindustry, Galmed Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galmed Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galmed Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Galmed Pharmaceuticals's PB Ratio falls into.



Galmed Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Galmed Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2024)
=2.97/12.234
=0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Galmed Pharmaceuticals  (NAS:GLMD) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Galmed Pharmaceuticals PB Ratio Related Terms

Thank you for viewing the detailed overview of Galmed Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Galmed Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
16 Tiomkin Street, Tel Aviv, ISR, 6578317
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.